Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Regulatory News & FDA Approvals » Enigma Diagnostics Launches MDx System, Flu/RSV Assay with CE Mark

Enigma Diagnostics Launches MDx System, Flu/RSV Assay with CE Mark

Jan 16, 2014
|
Ben Butkus
Premium

Enigma Diagnostics said this week that it has received CE IVD marking for its Enigma ML system and first assay, a combined molecular test for influenza A/B and respiratory syncytial virus.

The CE mark is an important milestone for Salisbury, UK-based Enigma, which has been developing the Enigma ML (Mini Laboratory) — a real-time PCR-based point-of-care testing platform — since at least 2009. Enigma said that it will now begin marketing its system and FluAB-RSV assay in more than 30 countries recognizing the CE mark.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Even Bigger

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Got Into the Lab Machines

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Not Going to Pay

Science reports that a Dutch research funding agency is combating a ransomware attack.

Science Papers Present Haplotype-Resolved Genomes, MiRNA-Linked Complex Tied to Ribosomal Protein Production

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
16
Featured Webinar

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Sponsored by
Bio-Rad

Wastewater based epidemiology (WBE) has been established as a viable, valuable, and cost-effective means to monitor infectious disease within a community. 

Mar
18
Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
25
Featured Webinar

Virtual Molecular Tumor Board Series: What to Do with a ‘Negative’ Molecular Panel Case

Sponsored by
Foundation Medicine

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.

What's Popular?

In PCR

  1. Luminex Shares Surge on Rumor of Acquisition by DiaSorin

  2. German Nucleic Acid Sample Prep Startup Rides COVID-19 Testing, Automation Waves

    Premium

  3. Novacyt Obtains CE Mark for Extraction-Free COVID-19 PCR Test

  4. Walgreens to Sell Labcorp COVID-19 PCR Home Collection Kits Over-the-Counter

  5. Biocartis Reports 15 Percent Rise in 2020 Revenues

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.